arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

HARROW, INC.

HROW
$34.48 ▲ +0.56 (+1.65%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
81 Visible periods
32 Metrics
Peer-ranked Benchmarks
Price Chart
36
Health
Weak
Bearish
auto_awesome

Analytical Summary

HARROW, INC. faces fundamental challenges with weakness in Debt to Equity. The fundamentals warrant careful consideration of downside risks.

Market Cap $1.3B
Dividend Yield
Revenue Growth 10.9%
Op. Margin -15.6%
ROIC -72.4%
FCF / Share $-0.27
Trailing P/E
Price / Book 85.0x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Sep 22, 2026.

81-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$70.66M
↑ +10.9%
Net Income Profit after all expenses
$-17.27M
↑ +37.4%
Operating Margin Operating profit as % of sales
-15.6%
↑ +68.8% 59th
FCF / Share Free cash flow per share
$-0.27
↓ -11.2%
Long-Term Debt Long-term obligations
$300.00M
↑ +20.0%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Debt to EquityDebt to Equity is concerning (bottom quartile)

Health Breakdown

Profitability
54
Returns
34
Financial Health
31
Cash Quality
2

bar_chart Data from SEC EDGAR XBRL filings

Synced yesterday 29 years · 81 quarters